top of page

August 6, 2025

Malone Wealth Advises Genius Group Ltd. on Strategic Investment in Quantum BioPharma (QNTM)

​


Boise, Idaho, July 28, 2025 — Malone Wealth Ventures, LLC (“Malone Wealth” or the “Firm”), a fiduciary investment advisory firm committed to client protection and value-based investing, today announced that Genius Group Ltd. (NYSE: GNS) has purchased 2,000 shares of Quantum BioPharma Ltd. (NASDAQ: QNTM) on Friday, August 1, at a price of $24.13 to hold on the Company’s balance sheet as a strategic investment.

​This transaction follows extensive consultation and analysis conducted by Malone Wealth, which advised the Company to make this purchase based on three key pillars:

​

  • The deep underlying value of Quantum BioPharma’s intellectual property, $700 million lawsuit, and strategic assets
     

  • The Company’s alignment with Genius Group’s mission to expose market corruption and enhance shareholder protections
     

  • Legal and financial synergies with Genius Group’s anticipated RICO action against entities engaging in naked short selling and market manipulation
     

Genius Group has been an outspoken advocate for market integrity and financial transparency. Its acquisition of Quantum BioPharma shares represents a tactical investment in a company actively fighting many of the same systemic abuses that Genius Group is seeking to expose through ongoing legal action and regulatory engagement.

​

“This isn’t just a deep-value investment,  it’s two companies joining forces to fight for what’s right,” said Kevin Malone, CEO of Malone Wealth and Board Advisor to Genius Group. “Quantum BioPharma has shown it’s not afraid to take on the system. We believe this move will help both companies stand stronger together and create real value for shareholders.”

​

This investment complements Genius Group’s broader legal and strategic framework, including:

​

  • Its pending RICO lawsuit against multiple broker-dealers and market participants
     

  • Active campaigns for regulatory reform across U.S. and international exchanges
     

  • Educational initiatives to empower retail investors with financial literacy and market transparency tools
     

The 2,000 shares of QNTM were acquired on the open market and are expected to be held on Genius Group’s balance sheet as a long-term strategic asset.

​

Malone Wealth Ventures, LLC continues to act as a strategic advisor to Genius Group Ltd., helping the Company identify and evaluate asymmetric opportunities across capital markets that align with Genius Group’s mission to build a transparent, decentralized, and investor-first financial system.

​

As with prior strategic investments, Genius Group intends for this stake to further its treasury strategy of accumulating undervalued, high-integrity assets with synergistic alignment to its legal and ethical mission.

 

About Genius Group Ltd.
Genius Group (NYSE: GNS) is a global education company committed to disrupting the traditional education model and building a decentralized, AI-powered lifelong learning system. The Company operates a global group of EdTech and education companies serving students, entrepreneurs, and investors through a personalized, mentor-led pathway. Genius Group is also a vocal advocate for retail investor protections, regulatory reform, and exposing market manipulation through public and legal channels.

For more information on Genius Group, please visit www.geniusgroup.net.

 

Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable securities laws. These forward-looking statements include, but are not limited to, statements regarding the strategic rationale for the investment in Quantum BioPharma Ltd., potential legal outcomes, and the anticipated benefits to Genius Group Ltd. from this transaction. Actual results may differ materially from those projected in the forward-looking statements due to various risks and uncertainties, including changes in market conditions, legal developments, and regulatory outcomes. Genius Group is under no obligation to update or revise forward-looking statements, except as required by law.

 

Contact:
Kevin Malone
CEO and President
Malone Wealth Ventures, LLC

Malone Wealth Ventures LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Malone Wealth Ventures LLC and its representatives are properly licensed or exempt from licensure. This website is solely for informational purposes. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital. No advice may be rendered by Malone Wealth Ventures LLC unless a client service agreement is in place.

bottom of page